There remains a lack of consensus among guideline relating to which patients 39 require investigation for haematuria. We determined the incidence of urinary tract 40 cancer in a prospective observational study of 3556 patients referred for 41 investigation of haematuria across 40 hospitals between March 2016 and June 2017 42 (DETECT 1; ClinicalTrials.gov: NCT02676180) and the appropriateness of age at 43 presentation in cases with visible (VH) and non-visible haematuria (NVH
There remains a lack of consensus among guideline relating to which patients 67 require investigation for haematuria [1] . In 2015, the UK National Institute for Health 68 and Care Excellence (NICE) recommended that patients aged ≥45 years with visible 69 haematuria (VH) and ≥60 years with non-visible haematuria (NVH) with either 70 dysuria or raised white cell count on blood test should be urgently referred on a 71 suspected cancer pathway [2] . The American Urology Association (AUA) 72 recommends that all patients with VH and patients with microscopic haematuria (≥3 73 red blood cells/ high power field) ≥35 years should be investigated [3] . In contrast, 74 the National Board of Health and Welfare of Sweden do not recommended 75 investigating NVH cases [4] . 76 The DETECT I study is a prospective multi-centre observational study recruiting 77 patients referred for investigation of haematuria [5] . We report the incidence of 78 urinary tract cancer in cases referred for investigation of haematuria and specifically 79 addressing whether age at presentation can be applied as a threshold for referral of 80 haematuria investigation. 81 Between March 2016 and June 2017, 3556 patients from 40 hospitals were recruited 82 ( Supplementary Fig 1) [6, 7] . The reference standard for upper tract cancer 89 diagnosis was based on multidisciplinary team meeting consensus following review 90 of imaging. The full trial protocol has been previously reported [5] .
91
Patient demographics according to diagnosis of urinary tract cancer is described in 92 This study underpins the importance of investigating patients presenting with 119 haematuria. We highlight that an age threshold cannot be assigned in patients with 120 VH and applying an age threshold defined by NICE will fail to detect clinically 121 significant disease. To our knowledge, this study is the first to confirm that cancers 122 detected in patients presenting with NVH are high risk with a significant number of 123 MIBC. Applying the NICE defined age threshold will fail to detect 10.5 % of cancers 124 with NVH (incident: 1.0%) and 2.2% of cancers with VH (incidence: 3.5%). All 125 cancers would be detected using AUA age thresholds.
126
NICE suggests that a sign or symptom associated with ≥3% risk of cancer should 127 prompt referral for diagnostic tests [2] . Our results suggest a case for the 128 investigation of all patients with VH. The following NVH is less clear with a cancer 129 incident rate of <3%. However, the overall incidence of urinary tract cancer in females investigated for NVH is actually similar to that of patients aged between 40-131 59 years, both below the 3% threshold. However, the knowledge that cancers 132 diagnosed following a presentation of NVH are clinically significant highlights the 133 importance of considering patient preference.
134
The importance of patient preference has recently been highlighted using a vignette 135 study to explore the likelihood that patients would want diagnostic tests if there was a 136 risk of cancer diagnosis [8] . Banks and colleagues showed that 85% of patients 137 would want referral for investigation for a symptom attributing a 1% risk of cancer, 138 even if invasive testing is required such as colonoscopy for colon cancer [8] . 139 An important limitation of the study is accrual of cases was by sampling individual 140 haematuria clinics rather than recruiting all patients during a defined time period.
141
However, patients were recruited before cystoscopy to exclude selection bias based 142 on diagnosis. The incidence of urinary tract cancer in patients with haematuria from 143 this study represents detection rate in secondary care and this will be higher than 144 patients in primary care. 145 This study suggests that patients with VH should be investigated regardless of age.
146
A decision to investigate NVH should reflect patient choice and public health policy.
147
What is clear is that there is a lack of consensus across guideline bodies and a 148 European wide guideline would aid physician decision making and patient selection 149 for referral for investigation of haematuria. 
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Take home message
Visible haematuria should be investigated regardless of age. While the risk of urinary tract cancer in patients <60 years with NVH is low, clinically significant bladder cancers are still diagnosed. European wide consensus for haematuria should be developed. 
